RxDoctor Payments Data

Jared Younger, MD

Ophthalmology · Fountain Valley, CANPI 1740492271

Payments from drug & device makers

$62,335in general payments, 2019–2025

Across 217 payments — averaging $287.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$56K
  • Lensar, Inc.$2K
  • Katena Products, Inc. (dba Corza Medical)$2K
  • AbbVie$551
  • Johnson & Johnson Vision Care, Inc.$453
  • Sun Pharmaceutical Industries Inc.$432
  • plus $2K from 23 others

What the payments were for

  • Royalty or licence$8471%
  • Consulting fees$47,76377%
  • Speaking & faculty fees$4,7338%
  • Travel & lodging$1,7943%
  • Food & beverage$7,17512%
  • Entertainment$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,335 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$356,518
Medicare patients
778
Services billed
2,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine97$116,583
Cyclosporine66$40,469
LumiganBimatoprost35$22,828
CombiganBrimonidine Tartrate/Timolol13$7,284
Alphagan PBrimonidine Tartrate19$6,301
Prednisolone Acetate166$5,734
Difluprednate40$5,297
Latanoprost324$5,088
ProlensaBromfenac Sodium15$4,503
SimbrinzaBrinzolamide/Brimonidine Tart19$4,257
Bromfenac Sodium17$3,281
Brimonidine Tartrate33$2,174
MoxifloxacinMoxifloxacin Hcl97$1,928
Tobramycin-DexamethasoneTobramycin/Dexamethasone35$1,319
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat36$1,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$551$152,995164 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$256$4,50315 claims
AlconSimbrinza$386$4,25719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →